Publications by authors named "Margaret Schermerhorn"
Objective: This study aimed to evaluate if an estimated fetal weight (EFW) between 10 and 15th percentiles at the time of anatomy ultrasound, referred to as borderline fetal growth, is associated with progression to fetal growth restriction (FGR) on subsequent ultrasound, delivery of a small for gestational age (SGA) neonate, or neonatal intensive care (NICU) admission.
Study Design: We performed a secondary analysis using the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMom2b) data. The exposures were normotensive pregnancies with non-anomalous singleton gestations with normal growth, defined as EFW >15th percentile at the anatomy scan compared to borderline fetal growth fetuses defined as those with an EFW in the 10 to 15th percentiles.
Massive perivillous fibrin deposition (MPVFD) is a potentially devastating complication of pregnancy that occurs in 0.03-0.5% of deliveries and is associated with severe fetal growth restriction, stillbirth, and neurologic injury due to uteroplacental insufficiency.
View Article and Find Full Text PDFBackground: Despite improvements, disparities in breast cancer care have led to an inequitable distribution of treatment delays and worse outcomes among patients with breast cancer. This study aimed to quantify the contribution of mediators that may explain racial/ethnic disparities in breast cancer treatment delays.
Patients And Methods: We conducted a retrospective analysis of patients from the National Cancer Database with stage I-III breast cancer who underwent surgical resection.
Article Synopsis
- A randomized trial was conducted at 34 US hospitals to assess the effectiveness of hydroxychloroquine for treating hospitalized adults with COVID-19, enrolling 479 patients from April to June 2020 and stopping early due to futility.
- Participants were divided into two groups, receiving either hydroxychloroquine or a placebo, with primary outcomes measured 14 days post-randomization using a 7-category scale.
- Results showed that despite a diverse patient sample, hydroxychloroquine did not demonstrate improved clinical outcomes compared to the placebo, leading to a conclusion of its ineffectiveness for this patient population.